M-protein de novo sequencing and tracking

downstream-application

M-protein de novo sequencing and tracking: downstream-application. De novo sequencing of the patient-specific M-protein followed by a targeted MS/MS assay tracks multiple myeloma in serum far more sensitively than SPEP or IFE.

De novo sequencing of the patient-specific M-protein followed by a targeted MS/MS assay tracks multiple myeloma in serum far more sensitively than SPEP or IFE.

Kind	downstream-application
Deep learning	no
Acquisition	DDA
Application area	Antibodyomics

Data

What the papers describing this method trained it on and reported its results on, as each paper states it. A version is named only where the paper names one.

Deposited

• Mass spectrometry provides a highly sensitive non-invasive means of sequencing and tracking M-protein levels in blood of multiple myeloma patients (as deposited)

Paper describing it

• Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients (2021, Journal of Proteome Research, peer-reviewed)

Authors (5)

Zac McDonald, Paul Taylor, Mariya Liyasova, Qixin Liu, Bin Ma

Seen in the charts

• Application areas
• Models and the authors behind them

Back to the full map